Inosi Therapeutics was awarded a $968,192 funding package from the Targeted Translation Research Accelerator (TTRA) initiative to advance its investigational treatment for Diabetic Kidney Disease into Investigational New Drug (IND)-enabling studies. The grant was part of the TTRA Diabetes and Cardiovascular Disease programme, delivered by MTPConnect through the Medical Research Future Fund.
The Melbourne-based biotechnology company’s lead initiative has been centred on the development of therapies aimed at halting or reversing fibrosis – a key driver in chronic conditions such as kidney and cardiovascular disease. These disorders continue to represent a significant burden for patients and health systems, with current treatment options offering limited efficacy.
The grant support was complemented by a further $2 million in investment co-led by IP Group and BioCurate, which will be used to strengthen Inosi’s broader anti-fibrotic research pipeline.
“The TTRA programme has been structured to bridge the gap between research and real-world impact, and aligns strongly with our translational goals,” said Filippa Shub, Chief Operating Officer at Inosi Therapeutics. “We’re excited to collaborate with the TTRA team to accelerate our clinical progress.”
Additional backing was expressed by co-investors. Dr Kathy Nielsen, Chief Executive Officer of BioCurate, remarked, “This therapeutic approach could significantly alter the treatment landscape for kidney disease, potentially reducing reliance on dialysis and organ transplantation.”
Dr Siro Perez, Partner and Head of Life Sciences, APAC at IP Group Australia, also commented, “Inosi Therapeutics represents the kind of cutting-edge research we are committed to supporting, and we’re pleased to contribute to its growth and development.”
The underlying technology was licensed from Monash University, with the project emerging from a collaborative effort involving the University of Melbourne, St Vincent’s Institute of Medical Research, and the Florey Institute of Neuroscience and Mental Health.
